Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
UTHR [NASD]
United Therapeutics Corporation
Index- P/E30.09 EPS (ttm)6.16 Insider Own0.10% Shs Outstand46.67M Perf Week-0.81%
Market Cap8.65B Forward P/E15.36 EPS next Y12.07 Insider Trans-95.10% Shs Float46.07M Perf Month5.41%
Income340.10M PEG1.72 EPS next Q2.26 Inst Own- Short Float10.98% Perf Quarter31.36%
Sales1.29B P/S6.71 EPS this Y91.50% Inst Trans-3.25% Short Ratio8.14 Perf Half Y49.00%
Book/sh26.69 P/B6.94 EPS next Y24.15% ROA17.00% Target Price154.57 Perf Year92.65%
Cash/sh14.90 P/C12.44 EPS next 5Y17.45% ROE26.90% 52W Range84.63 - 190.29 Perf YTD43.12%
Dividend- P/FCF28.10 EPS past 5Y79.20% ROI25.40% 52W High-2.61% Beta1.41
Dividend %- Quick Ratio1.80 Sales past 5Y29.10% Gross Margin90.20% 52W Low118.99% ATR5.57
Employees740 Current Ratio1.90 Sales Q/Q19.90% Oper. Margin41.80% RSI (14)64.15 Volatility2.52% 3.24%
OptionableYes Debt/Eq0.10 EPS Q/Q461.70% Profit Margin26.40% Rel Volume0.72 Prev Close185.19
ShortableYes LT Debt/Eq0.00 EarningsMay 26 BMO Payout0.00% Avg Volume621.57K Price185.33
Recom2.50 SMA203.44% SMA5011.48% SMA20041.24% Volume450,482 Change0.08%
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
Feb-26-15Reiterated H.C. Wainwright Buy $150 → $175
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Jul-30-14Reiterated H.C. Wainwright Buy $120 → $150
Apr-07-14Upgrade Standpoint Research Hold → Buy $118
Feb-26-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
Feb-26-14Reiterated Ladenburg Thalmann Buy $138 → $135
Dec-31-13Reiterated Argus Buy $120 → $130
Dec-23-13Upgrade Ladenburg Thalmann Neutral → Buy $138
Dec-02-13Reiterated Argus Buy $85 → $110
Aug-05-13Reiterated Argus Buy $75 → $85
Jul-30-13Downgrade Standpoint Research Buy → Hold
Jun-20-13Upgrade Standpoint Research Hold → Buy
May-15-13Downgrade Standpoint Research Buy → Hold
Mar-25-13Reiterated Ladenburg Thalmann Buy $69 → $63
Feb-27-13Reiterated RBC Capital Mkts Sector Perform $45 → $50
Aug-03-12Downgrade Standpoint Research Buy → Hold
Apr-16-15 01:35PM  United Therapeutics Corporation (UTHR), Amgen, Inc. (AMGN): Neil Shahs Top Healthcare Picks Dominated S&P 500 Index in January-March at Insider Monkey
Mar-30-15 06:04PM  MedImmune, Tech Council of Maryland chart path for region's biotech community at bizjournals.com
Mar-27-15 04:11PM  Era Group Inc (ERA), BioMarin Pharmaceutical Inc. (BMRN), & Assured Guaranty Ltd. (AGO) Among Stocks Amici Capital Is Bullish on at Insider Monkey
Mar-26-15 08:48AM  United Therapeutics (UTHR) Crumbles: Stock Falls by 6.5% - Tale of the Tape
Mar-25-15 10:03AM  Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)s 18% Spike at Insider Monkey -6.50%
Mar-19-15 03:15PM  Retrophin Soars on FDA Approval of Bile Acid Disorder Drug - Analyst Blog
11:12AM  Akorn, Inc. (AKRX), United Therapeutics Corporation (UTHR) Among Consonance Capitals Winning Bets in Healthcare at Insider Monkey
Mar-18-15 01:00PM  To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher at bizjournals.com
Mar-17-15 03:15PM  SteadyMed hopes to break Bay Area IPO lull with $68.4M offering this week at bizjournals.com
Mar-13-15 01:19PM  Watch these drug stocks Monday
08:46AM  These new meds could move stocks
Mar-12-15 09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Pharmacyclics, Amgen, United Therapeutics and Regeneron - Press Releases
07:27AM  United Therapeutics upgraded by Argus
Mar-11-15 05:40PM  United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog
Mar-10-15 06:47PM  United Therapeutics
03:17PM  United Therapeutics Wins FDA Nod, Priority Voucher at Investor's Business Daily
11:28AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
11:18AM  United Therapeutics Receives a Rare Pediatric Disease Priority Review Voucher following the Approval of Unituxin for Pediatric High-Risk Neuroblastoma PR Newswire
11:12AM  FDA Approves Unituxin (dinutuximab) for the Treatment of Pediatric High-Risk Neuroblastoma PR Newswire
10:29AM  FDA approves United Therapeutics' drug for treating cancer in children Reuters
Feb-28-15 01:04PM  UNITED THERAPEUTICS CORP Financials
Feb-26-15 07:08PM  10-K for United Therapeutics Corp. Company Spotlight
Feb-25-15 02:59PM  Stocks Mixed; United Therapeutics Jumps To New High at Investor's Business Daily
10:40AM  United Therapeutics Beats on Q4 Earnings & Revenues - Analyst Blog Zacks
06:00AM  United Therapeutics Corporation To Present At The Cowen And Company 35th Annual Healthcare Conference PR Newswire
Feb-24-15 06:17PM  Jazz Pharma Tops, But Stock Falls On Guidance Investor's Business Daily
11:58AM  United Therapeutics beats Street 4Q forecasts AP
10:04AM  United Therapeutics Blood Pressure Drug Lifts Q4 at Investor's Business Daily
07:07AM  Q4 2014 United Therapeutics Corp Earnings Release - Before Market Open CCBN
06:15AM  UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report EDGAR Online
06:14AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:00AM  United Therapeutics Corporation Reports 2014 Fourth Quarter And Annual Financial Results PR Newswire
Feb-18-15 04:39PM  Wednesday's Market Recap Yahoo Finance Contributors
Feb-17-15 06:00AM  United Therapeutics Corporation To Announce Fourth Quarter And Annual 2014 Financial Results Before Market Open On Tuesday, February 24, 2015 PR Newswire
Feb-05-15 06:32PM  Hot Growth Stocks: What Sectors Lead 2015 Now? at Investor's Business Daily
Jan-16-15 06:44PM  Ulta Among IBD 50 Stocks Setting Up In Shaky Market at Investor's Business Daily
02:20PM  Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog Zacks
Jan-15-15 05:33PM  NetEase, Other Leading Stocks Break Out To New Highs at Investor's Business Daily
12:50PM  Biotech Stock United Therapeutics Tests New Buy Point at Investor's Business Daily
Jan-06-15 09:50PM  United Therapeutics Corporation To Present At 33rd Annual J.P. Morgan Healthcare Conference PR Newswire
01:03PM  UPDATE: Barclays Initiates Coverage On United Therapeutics Benzinga
Jan-05-15 07:14PM  UPDATE: BTIG Initiates Coverage On United Therapeutics Benzinga
Dec-31-14 06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
06:00AM  United Therapeutics Announces Signing Of Agreement For New Remodulin Delivery System PR Newswire
Dec-24-14 11:48AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
11:26AM  United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin PR Newswire
Dec-19-14 05:20PM  United Therapeutics Lung Drug Keeps Going And Going at Investor's Business Daily
Dec-17-14 06:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princ EDGAR Online
06:00AM  United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change PR Newswire
Dec-11-14 11:48AM  Can United Therapeutics find a remedy for recent resistance? at Investor's Business Daily
Dec-08-14 01:25PM  Stocks Fall To Session Lows: GoPro Gives Up More Ground at Investor's Business Daily
Nov-26-14 05:40PM  Stock Market Today: Top Biotech Is Near Buy Point at Investor's Business Daily
Nov-13-14 06:44AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
06:00AM  Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors PR Newswire
Oct-30-14 08:08PM  10-Q for United Therapeutics Corp. Company Spotlight
07:59PM  Apple CEO publicly acknowledges that he's gay AP
Oct-29-14 11:50AM  United Therapeutics Falls on Q3 Loss, Revenues Miss Zacks
Oct-28-14 07:07AM  Q3 2014 United Therapeutics Corp Earnings Release - Before Market Open CCBN
06:27AM  United Therapeutics reports 3Q loss AP
06:05AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:04AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports Third Quarter 2014 Financial Results PR Newswire
Oct-22-14 05:01PM  Biotechs Show Fed Chief's Not Much Of A Stock Analyst at Investor's Business Daily
Oct-21-14 06:00AM  United Therapeutics Corporation To Announce Third Quarter 2014 Financial Results Before Market Open On Tuesday, October 28, 2014 PR Newswire
Oct-14-14 05:05PM  Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Zacks
10:27AM  J&J Beats Q3 Earnings on Strong Drug Sales, Ups View Zacks
Sep-26-14 03:07PM  Biotech's future: The Government is key Yahoo Finance
Sep-25-14 12:34PM  Artificial intelligence doppelgangers and life in outer space closer than you think Yahoo Finance
08:38AM  Highest-paid female CEO used to be a man Yahoo Finance
Sep-24-14 09:36AM  Can the Uptrend Continue for United Therapeutics (UTHR)? Zacks
Sep-23-14 05:21PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
08:10AM  Moving Average Crossover Alert: United Therapeutics (UTHR) Zacks
Sep-22-14 05:11PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
Sep-17-14 07:30AM  Axsome Therapeutics Announces Appointments to Its Board of Directors GlobeNewswire
Sep-16-14 03:00AM  Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market GlobeNewswire
Sep-15-14 05:32PM  Today's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
11:19AM  Hedge fund offers $1 million to cure...aging? at CNBC
Sep-10-14 04:20PM  Spectrum Pharmaceuticals to Advance Neutropenia Drug Zacks
Sep-09-14 03:50PM  Pluristem & United Therapeutics Progress with Phase I Study Zacks
Sep-03-14 04:20PM  Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Zacks
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
Sep-02-14 05:25PM  United Therapeutics Soars on Remodulin Patent Case Win Zacks
07:58AM  United Therapeutics (UTHR) Shares March Higher, Can It Continue? Zacks
Aug-29-14 04:21PM  United Therapeutics Legal Victory Sends Stock Flying at Investor's Business Daily +28.51%
02:21PM  United Therapeutics Up 27% as Patent Win 'Close to a Best Case Scenario' at Barrons.com
02:02PM  United Therapeutics rises on drug-patent ruling AP
12:49PM  District Court Decision Received In Remodulin Patent Case PR Newswire
Aug-26-14 07:50AM  Catalyst Pharmaceutical Partners (CPRX) Worth Watching: Stock Up 10.3% Zacks
Aug-25-14 11:05AM  Roche Buying InterMune for $8.3 Billion; Investors Want More Pharma Deals StockTwits
Aug-22-14 04:40PM  OncoGenex's Custirsen Passes First Interim Futility Analysis Zacks
08:25AM  Flamel Technologies SA (FLML) in Focus: Stock Rises 8% Zacks
Aug-21-14 08:56AM  Gilead (GILD) Hits 52-Week High Thanks to Sovaldi Zacks
Aug-20-14 05:21PM  Alcobra Starts Patient Enrollment for Mid-Stage Study on MDX Zacks
08:40AM  Salix Pharmaceuticals (SLXP) Jumps: Stock Moves 15.5% Higher Zacks
06:51AM  Can United Therapeutics (UTHR) Keep the Earnings Streak Alive This Quarter? Zacks
Aug-14-14 02:30PM  Rigel's R348 Fails in Phase II Study, Shares Down 13.6% Zacks
Jul-31-14 12:20PM  United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat Zacks
Jul-30-14 10:56AM  Perilous Reversal Watch: United Therapeutics (UTHR) at TheStreet -5.01%
07:08AM  United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session Zacks
Jul-29-14 07:07AM  Q2 2014 United Therapeutics Earnings Release - Before Market Open CCBN +8.10%
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & Co-CEOApr 20Option Exercise53.4215,322818,501594,387Apr 20 09:04 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 20Option Exercise52.652,592136,4692,832Apr 20 09:04 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 20Sale184.862,592479,163240Apr 20 09:04 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 16Option Exercise32.379,662312,7855,787Apr 16 09:30 PM
MAHON PAUL AEVP & General CounselApr 16Option Exercise33.146,000198,84041,054Apr 16 09:34 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 16Sale187.329,6621,809,852240Apr 16 09:30 PM
MAHON PAUL AEVP & General CounselApr 16Sale187.916,0001,127,46035,054Apr 16 09:34 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 15Option Exercise63.222,211139,7792,451Apr 16 09:30 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 15Sale185.692,211410,551240Apr 16 09:30 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerApr 14Option Exercise51.373,250166,9534,403Apr 14 07:04 PM
JEFFS ROGERPresident & Co-CEOApr 14Option Exercise47.5010,000475,00011,456Apr 14 07:08 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerApr 14Sale185.823,250603,9151,153Apr 14 07:04 PM
JEFFS ROGERPresident & Co-CEOApr 14Sale185.8210,0001,858,2001,456Apr 14 07:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 13Option Exercise53.4215,322818,501579,065Apr 13 08:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 13Option Exercise52.652,592136,4692,832Apr 13 08:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 13Sale187.862,592486,922240Apr 13 08:08 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 09Option Exercise32.379,662312,7855,787Apr 10 07:59 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerApr 09Option Exercise51.374,000205,4805,153Apr 10 08:05 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerApr 09Sale184.844,000739,3601,153Apr 10 08:05 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 09Sale183.099,6621,769,056240Apr 10 07:59 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 08Option Exercise63.222,211139,7792,451Apr 08 08:02 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 08Sale181.912,211402,203240Apr 08 08:02 PM
JEFFS ROGERPresident & Co-CEOApr 07Option Exercise47.5010,000475,00011,456Apr 08 07:55 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerApr 07Option Exercise51.374,000205,4805,153Apr 08 04:21 PM
JEFFS ROGERPresident & Co-CEOApr 07Sale179.3410,0001,793,4001,456Apr 08 07:55 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerApr 07Sale179.344,000717,3601,153Apr 08 04:21 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 06Option Exercise52.652,592136,4692,832Apr 06 07:56 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 06Option Exercise53.4215,322818,501563,743Apr 06 07:56 PM
ROTHBLATT MARTINE AChairman & Co-CEOApr 06Sale176.202,592456,701240Apr 06 07:56 PM
CAUSEY CHRISTOPHERDirectorApr 02Option Exercise44.633,000133,8752,233Apr 03 08:29 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerApr 02Option Exercise51.374,000205,4805,153Apr 03 08:32 AM
MAHON PAUL AEVP & General CounselApr 02Option Exercise33.146,000198,84041,054Apr 03 08:35 AM
ROTHBLATT MARTINE AChairman & Co-CEOApr 02Option Exercise32.379,662312,7855,787Apr 03 08:20 AM
CAUSEY CHRISTOPHERDirectorApr 02Sale174.223,000522,645733Apr 03 08:29 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerApr 02Sale174.734,000698,9201,153Apr 03 08:32 AM
MAHON PAUL AEVP & General CounselApr 02Sale174.736,0001,048,38035,054Apr 03 08:35 AM
ROTHBLATT MARTINE AChairman & Co-CEOApr 02Sale173.629,6621,677,479240Apr 03 08:20 AM
ROTHBLATT MARTINE AChairman & Co-CEOApr 01Option Exercise63.222,211139,7792,451Apr 03 08:20 AM
ROTHBLATT MARTINE AChairman & Co-CEOApr 01Sale172.592,211381,603240Apr 03 08:20 AM
JEFFS ROGERPresident & Co-CEOMar 31Option Exercise47.5010,000475,00011,456Apr 02 08:23 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMar 31Option Exercise51.374,000205,4805,153Apr 02 08:25 AM
JEFFS ROGERPresident & Co-CEOMar 31Sale172.4410,0001,724,3501,456Apr 02 08:23 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMar 31Sale172.444,000689,7401,153Apr 02 08:25 AM
ROTHBLATT MARTINE AChairman & Co-CEOMar 30Option Exercise52.652,592136,4692,832Mar 31 08:09 AM
ROTHBLATT MARTINE AChairman & Co-CEOMar 30Option Exercise53.4215,327818,768548,421Mar 31 08:09 AM
ROTHBLATT MARTINE AChairman & Co-CEOMar 30Sale177.222,592459,348240Mar 31 08:09 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMar 26Option Exercise51.374,000205,4805,153Mar 26 07:42 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 26Option Exercise32.379,662312,7855,787Mar 27 08:53 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMar 26Sale167.524,000670,0801,153Mar 26 07:42 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 26Sale167.039,6621,613,804240Mar 27 08:53 AM
ROTHBLATT MARTINE AChairman & Co-CEOMar 25Option Exercise63.222,211139,7792,451Mar 26 08:58 AM
ROTHBLATT MARTINE AChairman & Co-CEOMar 25Sale173.672,211383,974240Mar 26 08:58 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMar 24Option Exercise49.014,500220,5233,903Mar 24 09:22 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMar 24Sale179.514,500807,7951,153Mar 24 09:22 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 23Option Exercise52.652,592136,4692,832Mar 24 08:52 AM
ROTHBLATT MARTINE AChairman & Co-CEOMar 23Sale177.762,592460,766240Mar 24 08:52 AM
ROTHBLATT MARTINE AChairman & Co-CEOMar 19Option Exercise32.379,662312,7855,787Mar 24 07:21 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMar 19Option Exercise47.504,000190,0005,153Mar 24 07:21 AM
MAHON PAUL AEVP & General CounselMar 19Option Exercise33.146,000198,84041,054Mar 20 06:50 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 19Sale174.119,6621,682,281240Mar 24 07:21 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerMar 19Sale175.824,000703,2801,153Mar 24 07:21 AM
MAHON PAUL AEVP & General CounselMar 19Sale175.826,0001,054,92035,054Mar 20 06:50 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 18Option Exercise63.222,211139,7792,451Mar 18 05:57 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 18Sale174.642,211386,122240Mar 18 05:57 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 16Option Exercise52.652,592136,4692,832Mar 17 04:58 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 16Sale170.972,592443,164240Mar 17 04:58 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 12Option Exercise32.379,662312,7855,787Mar 13 04:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 12Sale163.179,6621,576,516240Mar 13 04:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 11Option Exercise63.222,211139,7792,451Mar 13 04:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 11Sale161.952,211358,065240Mar 13 04:27 PM
JEFFS ROGERPresident & Co-CEOMar 10Option Exercise50.098,750438,28810,206Mar 12 11:06 AM
JEFFS ROGERPresident & Co-CEOMar 10Sale163.848,7501,433,6001,456Mar 12 11:06 AM
MAHON PAUL AEVP & General CounselMar 05Option Exercise33.146,000198,84041,054Mar 06 06:38 PM
PATUSKY CHRISTOPHERDirectorMar 05Option Exercise41.145,000205,7005,000Mar 06 06:42 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 05Option Exercise32.379,662312,7855,787Mar 05 07:10 PM
DWEK RAYMONDDirectorMar 05Option Exercise31.173,00093,5103,000Mar 05 07:20 PM
CAUSEY CHRISTOPHERDirectorMar 05Option Exercise41.143,000123,4203,733Mar 05 07:25 PM
PATUSKY CHRISTOPHERDirectorMar 05Sale161.365,000806,8000Mar 06 06:42 PM
MAHON PAUL AEVP & General CounselMar 05Sale161.366,000968,16035,054Mar 06 06:38 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 05Sale159.759,6621,543,495240Mar 05 07:10 PM
DWEK RAYMONDDirectorMar 05Sale157.593,000472,7600Mar 05 07:20 PM
CAUSEY CHRISTOPHERDirectorMar 05Sale158.133,000474,386733Mar 05 07:25 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 04Option Exercise63.222,211139,7792,451Mar 05 08:37 AM
ROTHBLATT MARTINE AChairman & Co-CEOMar 04Sale157.632,211348,517240Mar 05 08:37 AM
JEFFS ROGERPresident & Co-CEOMar 03Option Exercise50.0910,000500,90011,234Mar 05 08:22 AM
JEFFS ROGERPresident & Co-CEOMar 03Sale157.7410,0001,577,4001,234Mar 05 08:22 AM
ROTHBLATT MARTINE AChairman & Co-CEOMar 02Option Exercise52.652,592136,4692,832Mar 02 06:51 PM
ROTHBLATT MARTINE AChairman & Co-CEOMar 02Sale155.322,592402,602240Mar 02 06:51 PM
Thompson Tommy GDirectorFeb 27Option Exercise52.657,500394,8757,500Feb 27 08:32 PM
PATUSKY CHRISTOPHERDirectorFeb 27Option Exercise51.777,500388,2757,500Feb 27 09:15 PM
KURZWEIL RAYDirectorFeb 27Option Exercise51.7715,000776,55015,000Feb 27 09:20 PM
PATUSKY CHRISTOPHERDirectorFeb 27Sale155.057,5001,162,8750Feb 27 09:15 PM
Thompson Tommy GDirectorFeb 27Sale153.637,5001,152,2380Feb 27 08:32 PM
KURZWEIL RAYDirectorFeb 27Sale155.0515,0002,325,7500Feb 27 09:20 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 26Option Exercise32.379,662312,7855,787Feb 26 05:10 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 26Sale155.239,6621,499,868240Feb 26 05:10 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 25Option Exercise63.222,211139,7792,451Feb 25 09:07 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 25Sale159.352,211352,317240Feb 25 09:07 PM
JEFFS ROGERPresident & Co-CEOFeb 24Option Exercise50.0910,000500,90011,234Feb 24 06:51 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerFeb 24Option Exercise50.091,45873,0312,611Feb 24 06:54 PM